New pill targets tough cancers in early human trial
NCT ID NCT04905914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to take pills by mouth and have a life expectancy of at least 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATRN-119 (oral capsule)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific DNA repair mutations.
What could go wrong
This is an early-phase trial (Phase 1/2a) with only 132 participants, so it is too small to prove effectiveness. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
NEXT Oncology- San Antonio
San Antonio, Texas, 78229, United States
-
NEXT Oncology- Virginia
Fairfax, Virginia, 22031, United States
-
NEXT- Oncology Dallas
Irving, Texas, 75039, United States
-
University Hospitals, Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States